milestones

Market Access

Capital depends on the strength of the science, the quality of execution, and the ability to deliver on milestones as planned.

News

Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.